Overview:

Dr. Chenxi HU joined NTD in 2023. His professional field focuses on the pharmaceutical and biotechnological industries, covering both small molecule drugs and biomacromolecules. Before joining NTD, Chenxi had been working at Beijing Zhongzi Law Office for 16 years. He has handled more than 1,000 patent applications so far, and has rich experience in patent prosecution, and is good at drafting patent applications and obtaining patents in China and other countries (including Europe, US, Japan, South Korea, India, etc.). Moreover, he has rich experience in patent invalidation, administrative litigation and infringement litigation, patent validity analysis, FTO analysis, etc., and has handled dozens of patent invalidation cases and litigation cases as an attorney, including some well-known cases. In addition, as a patent counsel for some pharmaceutical companies for a long time, he also has rich experience in patent strategy, patent mining, patent drafting, and infringement analysis for enterprises, and he helped a few start-up companies become a listed company.

Education and Training:

In 1998, graduated from the Department of Biochemistry of Nankai University with a bachelor's degree in science.


1998-2002, worked in biochemical research at Zhengzhou Tobacco Research Institute of China National Tobacco Corporation.

2002-2007, Ph.D. in Pharmacology, Institute of Materia Medica, Peking Union Medical College, Tsinghua University.

In 2011, studied European patent convention and patent practice in London, England and Munich, Germany.

Qualification:

 Patent Attorney

Technical Areas:

small molecule compounds, antibodies, biological macromolecules, organic synthesis, genetic engineering, ADCs, pharmaceutical formulations, diagnostic reagents, food product, etc.

Professional Affiliations:

 All-China Patent Attorneys Association (ACPAA) 

Working Language:

English, Mandarin

Representative cases:

Novartis vs. some domestic pharmaceutical companies, Entresto (sacubitril valsartan sodium) patent invalidation cases, representative of the patentee. The cases lasted five years and finally all of the patents were maintained valid.

Servier vs. Hongwen Chen, trimetazidine tablet patent invalidation case, representative of the patentee. Finally the patent was maintained valid.

Novartis vs. Jin Geng, TRAVATAN Z patent invalidation case, representative of the patentee. Finally the patent was maintained valid.